Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $257.8 million.

  • ImmunityBio's Cash & Current Investments rose 9775.94% to $257.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $257.8 million, marking a year-over-year increase of 9775.94%. This contributed to the annual value of $149.8 million for FY2024, which is 4377.85% down from last year.
  • ImmunityBio's Cash & Current Investments amounted to $257.8 million in Q3 2025, which was up 9775.94% from $153.7 million recorded in Q2 2025.
  • ImmunityBio's Cash & Current Investments' 5-year high stood at $317.1 million during Q4 2021, with a 5-year trough of $46.0 million in Q2 2023.
  • Its 5-year average for Cash & Current Investments is $148.1 million, with a median of $130.4 million in 2024.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first crashed by 6620.04% in 2022, then skyrocketed by 37434.17% in 2024.
  • ImmunityBio's Cash & Current Investments (Quarter) stood at $317.1 million in 2021, then tumbled by 66.2% to $107.2 million in 2022, then surged by 148.6% to $266.5 million in 2023, then plummeted by 43.78% to $149.8 million in 2024, then surged by 72.09% to $257.8 million in 2025.
  • Its last three reported values are $257.8 million in Q3 2025, $153.7 million for Q2 2025, and $61.6 million during Q1 2025.